These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 10700782)

  • 21. Novel skeletal muscle ryanodine receptor mutation in a large Brazilian family with malignant hyperthermia.
    McWilliams S; Nelson T; Sudo RT; Zapata-Sudo G; Batti M; Sambuughin N
    Clin Genet; 2002 Jul; 62(1):80-3. PubMed ID: 12123492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel double and single ryanodine receptor 1 variants in two Austrian malignant hyperthermia families.
    Kaufmann A; Kraft B; Michalek-Sauberer A; Weindlmayr M; Kress HG; Steinboeck F; Weigl LG
    Anesth Analg; 2012 May; 114(5):1017-25. PubMed ID: 22415532
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel mutations in C-terminal channel region of the ryanodine receptor in malignant hyperthermia patients.
    Oyamada H; Oguchi K; Saitoh N; Yamazawa T; Hirose K; Kawana Y; Wakatsuki K; Oguchi K; Tagami M; Hanaoka K; Endo M; Iino M
    Jpn J Pharmacol; 2002 Feb; 88(2):159-66. PubMed ID: 11928716
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic and functional analysis of the RYR1 mutation p.Thr84Met revealed a susceptibility to malignant hyperthermia.
    Kondo T; Yasuda T; Mukaida K; Otsuki S; Kanzaki R; Miyoshi H; Hamada H; Nishino I; Kawamoto M
    J Anesth; 2018 Apr; 32(2):174-181. PubMed ID: 29344738
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functional characterization of the RYR1 mutation p.Arg4737Trp associated with susceptibility to malignant hyperthermia.
    Johannsen S; Treves S; Müller CR; Mögele S; Schneiderbanger D; Roewer N; Schuster F
    Neuromuscul Disord; 2016 Jan; 26(1):21-5. PubMed ID: 26631338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence for a spontaneous C1840-T mutation in the RYR1 gene after DNA fingerprinting in a malignant hyperthermia susceptible family.
    Steinfath M; Seranski P; Singh S; Fiege M; Wappler F; Schulte Am Esch J; Scholz J
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Oct; 366(4):372-5. PubMed ID: 12237752
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel ryanodine receptor mutation that may cause malignant hyperthermia.
    Kaufmann A; Kraft B; Michalek-Sauberer A; Weigl LG
    Anesthesiology; 2008 Sep; 109(3):457-64. PubMed ID: 18719443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduced threshold for store overload-induced Ca
    Chen W; Koop A; Liu Y; Guo W; Wei J; Wang R; MacLennan DH; Dirksen RT; Chen SRW
    Biochem J; 2017 Aug; 474(16):2749-2761. PubMed ID: 28687594
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Malignant hyperthermia: an inherited disorder of skeletal muscle Ca+ regulation.
    Louis CF; Balog EM; Fruen BR
    Biosci Rep; 2001 Apr; 21(2):155-68. PubMed ID: 11725864
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heat- and anesthesia-induced malignant hyperthermia in an RyR1 knock-in mouse.
    Chelu MG; Goonasekera SA; Durham WJ; Tang W; Lueck JD; Riehl J; Pessah IN; Zhang P; Bhattacharjee MB; Dirksen RT; Hamilton SL
    FASEB J; 2006 Feb; 20(2):329-30. PubMed ID: 16284304
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Malignant hyperthermia: a pharmacogenetic disease of Ca++ regulating proteins.
    Nelson TE
    Curr Mol Med; 2002 Jun; 2(4):347-69. PubMed ID: 12108947
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel ryanodine receptor mutation and genotype-phenotype correlation in a large malignant hyperthermia New Zealand Maori pedigree.
    Brown RL; Pollock AN; Couchman KG; Hodges M; Hutchinson DO; Waaka R; Lynch P; McCarthy TV; Stowell KM
    Hum Mol Genet; 2000 Jun; 9(10):1515-24. PubMed ID: 10888602
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Functional characterization of 2 known ryanodine receptor mutations causing malignant hyperthermia.
    Schiemann AH; Paul N; Parker R; Pollock N; Bulger TF; Stowell KM
    Anesth Analg; 2014 Feb; 118(2):375-380. PubMed ID: 24361844
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impaired interaction between skeletal ryanodine receptors in malignant hyperthermia.
    Liang X; Chen K; Fruen B; Hu J; Ma J; Hu X; Parness J
    Integr Biol (Camb); 2009 Sep; 1(8-9):533-9. PubMed ID: 20023768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of ryanodine receptor mutations on interleukin-6 release and intracellular calcium homeostasis in human myotubes from malignant hyperthermia-susceptible individuals and patients affected by central core disease.
    Ducreux S; Zorzato F; Müller C; Sewry C; Muntoni F; Quinlivan R; Restagno G; Girard T; Treves S
    J Biol Chem; 2004 Oct; 279(42):43838-46. PubMed ID: 15299003
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Malignant hyperthermia and excitation-contraction coupling.
    Melzer W; Dietze B
    Acta Physiol Scand; 2001 Mar; 171(3):367-78. PubMed ID: 11412150
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Failure to identify the ryanodine receptor G1021A mutation in a large North American population with malignant hyperthermia.
    Stewart SL; Rosenberg H; Fletcher JE
    Clin Genet; 1998 Oct; 54(4):358-61. PubMed ID: 9831351
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Malignant hyperthermia susceptibility diagnosed with a family-specific ryanodine receptor gene type 1 mutation.
    Tanabe T; Fukusaki M; Terao Y; Yamashita K; Sumikawa K; Mukaida K; Ibarra CA; Nishino I
    J Anesth; 2008; 22(1):70-3. PubMed ID: 18306019
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Divergent Activity Profiles of Type 1 Ryanodine Receptor Channels Carrying Malignant Hyperthermia and Central Core Disease Mutations in the Amino-Terminal Region.
    Murayama T; Kurebayashi N; Yamazawa T; Oyamada H; Suzuki J; Kanemaru K; Oguchi K; Iino M; Sakurai T
    PLoS One; 2015; 10(6):e0130606. PubMed ID: 26115329
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genotype-Phenotype Correlations of Malignant Hyperthermia and Central Core Disease Mutations in the Central Region of the RYR1 Channel.
    Murayama T; Kurebayashi N; Ogawa H; Yamazawa T; Oyamada H; Suzuki J; Kanemaru K; Oguchi K; Iino M; Sakurai T
    Hum Mutat; 2016 Nov; 37(11):1231-1241. PubMed ID: 27586648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.